5 Top Losers In Healthcare Sector (GLYC, LOGC, KZR…)

(RTTNews) - The following are some of the healthcare stocks that posted the biggest percentage decline on Monday.

1. GlycoMimetics Inc. (GLYC)

GlycoMimetics is a clinical-stage biotechnology company focused on developing novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role.

Lost 69.33% to close Monday's (Aug.5) trading at $2.80.

News: The Company's phase III trial of Rivipansel in patients aged six and older with sickle cell disease who were hospitalized for a vaso-occlusive crisis and required treatment with intravenous opioids, dubbed RESET, did not meet its primary or key secondary efficacy endpoints.

The primary endpoint was time to readiness-for-discharge and the key secondary efficacy endpoints were time-to-discharge, cumulative IV opioid consumption, and time to discontinuation of IV opioids.

2. LogicBio Therapeutics Inc. (LOGC)

LogicBio is a genome editing company focused on developing medicines for rare diseases.

Lost 21.02% to close Monday's trading at $10.22.

News: No news

Clinical Trials & Near-term Catalysts:

The Company expects to file an IND for LB-001 in the fourth quarter of 2019 and initiate a Phase 1/2 trial in methylmalonic academia, an inborn error of metabolism, in 2020.

3. ESSA Pharma Inc. (EPIX)

ESSA is a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer.

Lost 19.58% to close Monday's trading at $1.52.

News: No news

Pipeline:

The Company's lead drug candidate is EPI-7386 for the treatment of metastatic castration-resistant prostate cancer. The IND-enabling studies are under progress, and the Company is on track to enter clinical studies with EPI-7386 in the first quarter of 2020.

4. Oncolytics Biotech Inc. (ONCY)

Lost 18.42% to close Monday's trading at $0.93. The stock hit an all-time low of $0.90 in intraday trading today.

News: No news

Clinical Trials & Near-term Catalyst:

An open-label window-of-opportunity study combining Pelareorep and Tecentriq in early-stage breast cancer, dubbed AWARE-1, is underway. The AWARE-1 trial is designed to enroll 38 patients into five cohorts.

On July 23, 2019, the Company announced the completion of the three patient run-in for the AWARE-1 study. The preliminary results demonstrated viral replication and promotion of inflammation following systemic administration of Pelareorep when combined with Tecentriq.

Interim data from the AWARE-1 trial is expected to be presented at a scientific conference before the end of the year.

5. Kezar Life Sciences Inc. (KZR)

Kezar is a clinical-stage biotechnology company developing novel small molecule therapeutics for patients with autoimmune diseases and cancer.

Lost 18.04% to close Monday's trading at $4.27.

News: No news

Recent event:

On June 13, 2019, the Company announced positive results from the Phase 1b open-label dose-escalation portion of the MISSION study evaluating KZR-616 in patients with systemic lupus erythematosus.

Clinical Trials & Near-term Catalysts:

-- A phase II trial of KZR-616 in lupus nephritis is underway. KZR-616 is also being explored in other indications, and phase II trials of the drug candidate in the treatment of dermatomyositis, polymyositis, autoimmune hemolytic anemia, and immune thrombocytopenia are expected to be initiated in the second half of this year.